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Abstract
Reductively metabolized glutamine is a major cellular carbon source for fatty acid synthesis
during hypoxia or when mitochondrial respiration is impaired. Yet, a mechanistic understanding
of what determines reductive metabolism is missing. Here we identify several cellular conditions
where the α-ketoglutarate/citrate ratio is changed due to altered acetyl-CoA to citrate conversion,
and demonstrate that reductive glutamine metabolism is initiated in response to perturbations that
results in an increase in the α-ketoglutarate/citrate ratio. Thus, targeting reductive glutamine
conversion for a therapeutic benefit might require distinct modulations of metabolite
concentrations rather than targeting the upstream signaling, which only indirectly affects the
process.
Uncontrolled cell proliferation associated with cancer necessitates metabolic alterations to
support rapid cell growth; hence understanding these changes is of critical importance in
identifying new and promising cancer therapies1, 2. While substantial progress has been
made in elucidating how altered signaling events promote uncontrolled proliferation in
cancer, our knowledge regarding the metabolic rearrangements that provide building blocks
for biomass, ATP, and generation of reducing equivalents remains limited3, 4. Recently, we
and other groups identified reductively metabolized glutamine as the major carbon source of
*corresponding author: gregstep@mit.edu.
6equal contribution
7present address: Vesalius Research Center, VIB, Heretstraat 49, 3000 Leuven, Belgium
Competing Financial Interests
The authors declare no competing financial interests.
Authors Contribution
SMF conceived and designed the study, performed experiments, measured mass distributions and metabolite levels, analyzed all data
and drafted the manuscript. ELB helped conceiving the study and helped drafting the manuscript. MAK performed oxygen
consumption measurements and helped with metabolite level quantification and labeling experiments. BAO performed western blot
analysis. JRM performed NAD+/NADH measurements and helped with metabolite level quantification. TMW measured ATP, ADP
and AMP and NIV helped with NAD+/NADH measurements. LG provided support and reagents. MGVH and GS provided conceptual
advice and helped drafting the manuscript. All authors read and approved the final manuscript.
NIH Public Access
Author Manuscript
Nat Commun. Author manuscript; available in PMC 2014 February 25.
Published in final edited form as:
Nat Commun. 2013 ; 4: 2236. doi:10.1038/ncomms3236.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
fatty acid synthesis during hypoxia and impaired respiration5, 6, 7, 8. Moreover, this switch in
carbon source selection was shown to be of particular importance for sustaining rapid cell
proliferation5, 7.
Both hypoxia and the loss of the Von-Hippel Lindau gene (VHL)9, 10 promote reductive
glutamine metabolism, while inhibition of pyruvate dehydrogenase kinase isoform 1
(PDK1), a target of the VHL-hypoxia inducible factor (HIF1α) axis 11, 12, also decreases
reductive glutamine utilization in various cell systems5, 7. Additionally, reductive glutamine
utilization is activated during impaired respiration, thereby raising the possibility that
alterations in NAD+/NADH metabolism might be involved6. However, a mechanistic
understanding of how hypoxia, respiratory impairment, and expression changes in VHL and
PDK1 all converge to impact reductive glutamine metabolism is lacking. As a result, the
prediction of how other environmental, genetic, or pharmacological interventions might
trigger reductive glutamine utilization is not possible.
In this study we aim to identify how the switch to reductive glutamine utilization is
controlled in cells. To this end we systematically measure changes in metabolite levels and
metabolic flux contributions in cancer cell lines following various cellular perturbations, and
examine the impact of these changes on reductive glutamine metabolism. We find that
reductive glutamine metabolism is a general phenomenon that occurs in response to any
intervention that increases the α-ketoglutarate/citrate ratio. Specifically, changes in this ratio
are predicted to increase reductive glutamine metabolism by mass action. Furthermore, in
most conditions tested, a decrease in acetyl-CoA (AcCoA) to citrate conversion, triggered
by one of at least two different mechanisms, is an event responsible for the alteration in the
α-ketoglutarate/citrate ratio, suggesting this as a key node in determining reductive
glutamine metabolism.
Results
Oxidative and reductive glutamine metabolism
In mammalian cells glutamine can be an important contributor of carbon to the TCA
cycle13, 14 where it can be metabolized in the oxidative or reductive direction5, 6. Reductive
glutamine metabolism involves the conversion of α-ketoglutarate to citrate and acts as a
carbon source to fuel fatty acid synthesis (Figure 1a). In oxidative glutamine metabolism, α-
ketoglutarate is oxidized to succinate for the eventual conversion to citrate by the TCA
cycle. Interconversion of citrate and isocitrate is necessary for the TCA cycle to operate in
either direction; this reaction is often found close to equilibrium such that isocitrate is
maintained at approximately 6.5% of the citrate concentration15. We experimentally
validated the equilibrium assumption for the culture conditions and treatments tested here,
and found the isocitrate concentration to be 4.1% ± 0.79% of the citrate concentration under
standard culture condition and 5.3% ± 0.85% of the citrate concentration following
metformin treatment. Therefore, to simplify our analysis we focused our measurements on
citrate as the more abundant metabolite. Because α-ketoglutarate and citrate levels represent
the substrate or product in key reactions of reductive versus oxidative glutamine
metabolism, their levels are predicted to be critical parameters in determining the reaction
direction. While both metabolites are present in the cytosol and the mitochondria we
analyzed the total pool size due to the lack of established methods to quantitatively separate
the two pools. Furthermore, we decided to specifically focus on the reductive glutamine
contribution instead of the reductive net flux, because net fluxes per se are also a function of
growth rate16. Because many of the perturbations used in this study influence cell growth, it
is impossible to control for secondary effects on net flux resulting from changes in cell
growth.
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Reductive carboxylation is regulated on a metabolic level
To elucidate the mechanism responsible for the switch from oxidative to reductive
glutamine utilization, we measured reductive glutamine contribution to citrate and changes
in the levels of citrate and α-ketoglutarate using U-13C glutamine and gas chromatography -
mass spectrometry5. We compared cells under conditions previously described to induce
reductive glutamine metabolism: hypoxia, or treatment with rotenone, metformin, and
antimycin a 5, 6, 7, 8. The respiratory chain inhibitors rotenone, metformin and antimycin a
were all used at concentrations that cause an approximately 50% decrease in oxygen
consumption (Supplementary Figure S1). As expected, reductive glutamine contribution to
citrate (identified by the level of the M+5 mass isotopomer of citrate from U-13C glutamine
(Supplementary Figure S2a)) increased for all conditions compared to the control condition
(Figure 1b). Furthermore, the citrate and α-ketoglutarate levels decreased in all conditions;
however, the decrease in citrate was much greater than the decrease in α-ketoglutarate
(Figure 1c). Strikingly, the α-ketoglutarate/citrate ratio correlated with the magnitude of
reductive glutamine contribution to citrate (Figure 1 b, c, e; Supplementary Data 1). This
suggests that changes in the α-ketoglutarate/citrate ratio could be the principal driving force
for the switch from oxidative glucose to reductive glutamine metabolism, promoting the use
of glutamine as the primary carbon source for citrate synthesis. Because lipogenic AcCoA is
derived from citrate5, this ratio might determine the source of carbon for lipid synthesis
(Figure 1a).
The correlation between reductive glutamine contribution to citrate and increased α-
ketoglutarate/citrate ratio raises the question of how this ratio is determined. Besides
glutamine also glucose can contribute to citrate and α-ketoglutarate levels17. We inferred the
latter flux contribution with a U-13C glucose tracer by measuring the total glucose
contribution to citrate or the AcCoA contribution to α-ketoglutarate. Total glucose
contribution to citrate, and AcCoA contribution to α-ketoglutarate (M+2 of α-ketoglutarate
from U-13C glucose (Supplementary Figure S2b)), decreased in all conditions compared to
control (Figure 1d). Moreover, the percent of M+2 α-ketoglutarate from U-13C glucose and
the percent citrate labeling from glucose both correlated inversely with the reductive
glutamine contribution to citrate (Figure 1b, d, f), and thus the α-ketoglutarate/citrate ratio
(Figure 1c, d). This suggests that carbon entry into the TCA cycle via AcCoA, can affect the
α-ketoglutarate/citrate ratio, and suggest this as one point of regulation.
If carbon entry into the TCA cycle via AcCoA regulates the α-ketoglutarate/citrate ratio and
reductive glutamine contribution to citrate then replenishing the pyruvate-derived citrate
pool by forcing carbon into the TCA cycle via AcCoA should decrease reductive glutamine
utilization. Increased glucose concentrations cannot be used to increase the oxidative carbon
entry into the TCA cycle. However, since glucose can be converted to lactate,
supplementing the media with high concentrations of lactate can impair cytosolic NAD+
regeneration and promote increased carbon contribution via AcCoA into the TCA cycle.
Addition of lactate to the culture media shifts the reaction direction of lactate dehydrogenase
from net synthesis to net consumption of lactate to produce pyruvate18. Because pyruvate-
to-lactate conversion is a major route of NAD+ regeneration from NADH, higher lactate
levels increase cytosolic NADH levels preventing cytosolic NAD+ recovery and increase
carbon contribution into the TCA cycle via AcCoA19 (Figure 2a). Moreover, lactate addition
uncouples the use of glucose-derived carbon, since both lactate and glucose feed into the
same pyruvate pool. Lactate supplementation in the control condition increased the AcCoA
contribution to α-ketoglutarate (M+3 in α-ketoglutarate from U-13C glutamine
(Supplementary Figure S2a)) and decreased the α-ketoglutarate/citrate ratio along with
reductive glutamine contribution to citrate (Supplementary Figure S3a). We confirmed the
increase in AcCoA contribution to α-ketoglutarate during lactate supplementation is a result
of increased pyruvate entry by comparing M+3 in α-ketoglutarate from U-13C glutamine to
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M+2 in α-ketoglutarate from U-13C lactate and U-13C glucose. We found that the sum of the
M+2 contributions from glucose and lactate matched the M+3 contribution from glutamine,
showing that supplementation of lactate leads to a joint contribution of glucose and lactate to
pyruvate and it’s entry into the AcCoA pool (Supplementary Figure S3b (left panel)).
Subsequently, we applied lactate supplementation to conditions that induce reductive
glutamine utilization and found that AcCoA contribution to α-ketoglutarate increased
(Figure 2b), and the α-ketoglutarate/citrate ratio decreased along with reductive glutamine
contribution to citrate (Figure 2c, d, Supplementary Data 1). We again confirmed using the
rotenone + lactate condition that both glucose and lactate contribute to the AcCoA pool
(Supplementary Figure S3b (right panel)). Notably, the effect seen following exposure to
hypoxia, rotenone and metformin was much more pronounced than for antimycin a. This
may be due to the fact that complex I inhibition can be circumvented using the glycerol
phosphate shuttle to pass electrons to complex II, while a block in complex III cannot be
bypassed20. Together, these data show that carbon conversion to citrate via AcCoA
modulates the α-ketoglutarate/citrate ratio, which in turn might determine the reductive
glutamine contribution to citrate.
To further test the hypothesis that the α-ketoglutarate/citrate ratio determines whether
glutamine is converted oxidatively (via glutamine anaplerosis) or reductively (via reductive
carboxylation), we reasoned that supplementing cells that have increased reductive
glutamine usage with acetate (to directly replenish the citrate pool (Figure 3a)) or citrate
should shift the ratio from reductive back to oxidative glutamine utilization. To test this
possibility, we added acetate (25mmol/L) or citrate (0.3 mmol/L and 1.2mmol/L) to cells in
the presence of metformin. In the presence of acetate we measured the α-ketoglutarate/
citrate ratio and reductive glutamine contribution to citrate normalized to the total glutamine
contribution to citrate with a U-13C glutamine tracer (Supplementary Figure S2a). This
normalization was undertaken to prevent the unlikely possibility that addition of acetate will
disturb metabolite pool size and thus lead to an overall decrease in glutamine contribution to
the metabolites. Acetate decreased the α-ketoglutarate/citrate ratio and similarly reduced the
normalized reductive glutamine contribution to citrate (Figure 3b,c). The addition of acetate
also led to increased oxidative glutamine metabolism in the TCA cycle.(Figure 3d).
Furthermore, we tested whether acetate supplementation to metformin treatment also
decreases the reductive glutamine contribution to palmitate using 5-13C glutamine (Figure
3e, Supplementary Figure S4). In line with the citrate labeling data, we measured reduced
5-13C glutamine labeling in m+5 to m+8 palmitate when acetate is supplemented in the
medium of metformin treated cells. This finding corroborates that the reductive conversion
of glutamine is reduced when acetate is added. With citrate supplementation, we measured
the ratio between oxidative and reductive glutamine utilization using a U-13C-glutamine
tracer. Measuring the α-ketoglutarate/citrate ratio in this condition is not possible due to
residual media citrate impeding accurate measurements of intracellular citrate levels. We
determined the ratio of oxidative versus reductive glutamine utilization based on M+4 in
fumarate, malate and aspartate (oxidative contribution) and M+3 in fumarate, malate and
aspartate (reductive contribution) (Supplementary Figure S2c). We found that the ratio
between oxidative and reductive glutamine utilization in the presence of metformin
increased with increasing citrate concentrations (Figure 3f), further arguing that the switch
from oxidative to reductive glutamine utilization is a function of the α-ketoglutarate/citrate
ratio.
To determine if glucose contribution to the TCA cycle and the α-ketoglutarate/citrate ratio
determines oxidative versus reductive glutamine metabolism in another cell line, we
measured glucose contribution to the TCA cycle along with the corresponding α-
ketoglutarate/citrate ratios under nine different growth conditions in 143B osteosarcoma
cells. Analysis of U-13C glucose and U-13C glutamine tracer data demonstrates that the
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levels of reductive glutamine contribution to citrate varied by 8 fold with treatments (Figure
4a; Supplementary Data 1). Addition of lactate, β-nicotinamide mononucleotide (NMN)
(NAD+ precursor) and the mitochondrial uncoupling agent FCCP decreased reductive
glutamine contribution, while addition of AICAR (a precursor of AMP) had only minor
effects that were not statistically significant. Oligomycin (a direct inhibitor of mitochondrial
ATP synthase), rotenone, metformin, and antimycin a all led to increased reductive
glutamine contribution to citrate (Figure 4a). The AcCoA contribution to α-ketoglutarate,
the total pyruvate contribution to citrate, citrate and α-ketoglutarate levels, as well as the α-
ketoglutarate/citrate ratio were correlated with reductive glutamine contribution to citrate
(Figure 4b–h). With the exception of lactate supplementation, total pyruvate contribution to
citrate is given based on the total glucose contribution to citrate. In the case of lactate the
total pyruvate contribution to citrate is resembled by the sum of the total glucose and lactate
contribution to citrate. Notably, for some stress conditions (lactate, oligomycin, rotenone,
and metformin) α-ketoglutarate instead of citrate is the major contributor to the change in
the α-ketoglutarate/citrate ratio (Figure 4d). Nonetheless, the α–ketoglutarate/citrate ration,
but not α-ketoglutarate or citrate levels themselves, correlate most strongly with the percent
reductive glutamine contribution to citrate (figure 4g and h). This observation strongly
argues that the ratio, rather than the α-ketoglutarate nor the citrate concentration themselves,
is the major determinant of reductive glutamine utilization. Thus, it is unlikely that α–
ketoglutarate (or isocitrate) concentrations per se regulates isocitrate dehydrogenase on the
enzyme level.
To expand our findings and exclude the possibility that the effects we observed could all be
accounted for by an increase in α-ketoglutarate-to-citrate carbon exchange or be
compromised by labeled CO2 fixation, we measured the reductive glutamine contribution to
the fatty acid palmitate in the PC3 prostate adenocarcinoma cell line (Figure 5;
Supplementary Data 1). Reductive glutamine contribution to palmitate was measured using
a 5-13C-glutamine tracer, which reaches palmitate only through reductive glutamine
metabolism (Supplementary Figure S4). The contribution of this tracer to palmitate was
calculated based on an isotopic spectral analysis model21, 22. The 9 conditions tested
spanned a 14-fold range of reductive glutamine contribution to palmitate (Figure 5). Similar
to the results obtained with citrate labeling in A549 and 143B cells, reductive glutamine
contribution to palmitate correlated with AcCoA contribution to α-ketoglutarate, the total
glucose contribution to citrate, and the α-ketoglutarate/citrate ratio (Figure 5). These results
further corroborate the hypothesis that the above mentioned criteria determine the extent of
reductive glutamine metabolism across a wide range of cellular conditions.
To further elucidate that an increase in reductive glutamine contribution to citrate results in a
net flux increase such as it has been shown previously for hypoxia5, we measured the net
reductive glutamine flux to palmitate in the presence of antimycin a, oligomycin or TTFA
(Supplementary Figure S5). In accordance with results observed under hypoxia, we found
that net reductive glutamine flux to palmitate increased in the presence of antimycin a,
oligomycin or TTFA by approximately six-, five and threefold, respectively (Supplementary
Figure S5). This data suggests that, at least in certain conditions, this major switch in carbon
fueling results also in a net flux increase.
Multiple upstream events influence TCA cycle carbon entry
To investigate if there is a sole signaling event that controls carbon entry into the TCA cycle
via AcCoA, we further tested how reductive glutamine contribution to citrate is regulated
under hypoxia and in the presence of complex I/III inhibitors (rotenone, metformin and
antimycin a). It has been shown previously that inhibition of PDK1 with DCA reduces the
contribution of reductive glutamine carboxylation in hypoxia5. To evaluate the extent by
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which PDKs impact reductive glutamine utilization, we determined the effect of the PDK
inhibitor dichloroacetate (DCA)23, 24 on the reductive glutamine contribution to citrate in the
presence of rotenone, metformin or antimycin a. The dose of DCA was adjusted to a
concentration that significantly reduced PDHE1a Ser232 phosphorylation in hypoxia
(Supplementary Figure S6). The concentration of 5mmol/L DCA that met these criteria
matches the concentration used previously5. Our data corroborated that PDK inhibition by
DCA significantly reduced reductive glutamine contribution to citrate in hypoxia (Figure
6a) 5, but DCA did not alter reductive carboxylation in the presence of complex I/III
inhibitors (Figure 6a) suggesting that these stresses may utilize distinct mechanisms.
One consequence of respiratory chain inhibition is decreased mitochondrial conversion of
NADH to NAD+ and thus a reduced mitochondrial NAD+/NADH ratio6, 25. Interestingly,
the pyruvate dehydrogenase reaction is coupled to this cofactor ratio17; therefore it is
possible that changes in the mitochondrial NAD+/NADH ratio following complex I/III
inhibition are responsible for reduced carbon entry into the TCA cycle via AcCoA. To test
this hypothesis, we measured the NAD+/NADH ratio using HPLC (Supplementary Figure
S8), in cells growing in standard culture conditions and under the four stress conditions. We
confirmed literature data that, indeed, the NAD+/NADH ratio decreased by more than
tenfold in the presence of complex I/III inhibitors compared to the control (Figure 6b);
however, there was no significant alteration of the NAD+/NADH ratio under hypoxia
(Figure 6b). We further estimated from the lactate to pyruvate ratio the amount of free
NAD+/NADH in the cytosol. As expected, the cytosolic lactate to pyruvate ratio26 increased
following rotenone, metformin and antimycin a treatment (Supplementary Figure S9)
suggesting that the total decrease in NAD+/NADH measured likely occurs mainly in the
mitochondria. Thus this ratio could mediate the directionality of glutamine metabolism in
the presence of respiratory inhibitors.
To test if the lower NAD+/NADH ratio limits carbon entry into the TCA cycle during
respiratory chain inhibition and to exclude a bias due to the fact that we can directly measure
only total but not free NAD+/NADH, we supplemented the media with the NAD+ precursor
NMN. Supplementation of cells with NMN increases the free NAD+ level27, thus increasing
the NAD+/NADH ratio (Figure 7a). As expected from literature data, NMN addition
increased the NAD+/NADH ratio in the presence of metformin by more than fivefold
compared to metformin alone (Figure 7b). Moreover, the AcCoA contribution to α-
ketoglutarate increased when NMN was added to metformin-treated cells, while the
reductive glutamine contribution decreased (Figure 7c,d). These data suggest that changes in
the NAD+/NADH ratio elicited by respiratory inhibitors changes the α-ketoglutarate/citrate
ratio, which in turn, shifts glutamine utilization from oxidative to reductive.
While the above data suggest that the NAD+/NADH ratio affects the pyruvate
dehydrogenase reaction, it is unclear if this happens directly via cofactor coupling or
indirectly via effects on pyruvate dehydrogenase kinase isoform 4 (PDK4) activity. Thus we
tested if PDK4 is expressed differently in hypoxia compared to the complex I/III inhibitors
(Supplementary Figure S3c). We found that PDK4 expression increased by approximately
threefold during metformin treatment compared to hypoxia. PDK4-mediated
phosphorylation inhibits pyruvate dehydrogenase activity and PDK4 is known to be strongly
regulated by the NAD+/NADH ratio28. If the pyruvate dehydrogenase complex is directly
inhibited by the NAD+/NADH ratio via cofactor coupling, instead of PDK4-mediated
phosphorylation, addition of NMN in the presence of DCA (which inhibits PDK428) and
metformin should still increase the AcCoA contribution to α-ketoglutarate (Figure 7a).
Thus, we added DCA at concentrations determined to block PDHE1a phosphorylation
(Supplementary Figure S6), and found that NMN increased AcCoA contribution to α-
ketoglutarate and as expected, decreased reductive glutamine contribution to citrate in the
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presence of metformin plus DCA, excluding the involvement of PDK4 (Figure 7e–f). While
the NAD+/NADH ratio can control carbon entry into the TCA cycle, and thus reductive
carboxylation, other regulatory events resulting from complex I/III inhibition cannot be
excluded. These data suggest that while alterations in PDH activity via phosphorylation can
promote reductive carboxylation, this is not the only mechanism active under all conditions.
Discussion
Reductive glutamine contribution to metabolites and biomass building blocks was recently
identified as a phenomenon to support growth of hypoxic and respiratory chain impaired
cells5, 6, 7, 8. We demonstrate here a general mechanistic explanation for how metabolic
rearrangements enable reductive glutamine contribution to citrate (Figure 8). Although our
approach is limited in looking at cell metabolite levels without information about
compartmentalization of pathways, with the consequence that we cannot provide
thermodynamic calculations, we identified the α-ketoglutarate/citrate ratio itself as a critical
determinant of reductive glutamine utilization. In some cases, this may not represent a true
increase in net flux, but a relative flux change with increased exchange may also be involved
as both lead to increased 5-carbon labeled citrate from glutamine. Nevertheless, altered α-
ketoglutarate/citrate ratios can promote increased net reductive glutamine flux under some
conditions including hypoxia5 or treatment with antimycin a, oligomycin or TTFA.
A wide range of conditions influence the α-ketoglutarate/citrate ratio by modulating carbon
entry into the TCA cycle via AcCoA. Moreover, our data demonstrate that other events (e.g.
acetate or citrate supplementation) that alter the α-ketoglutarate/citrate ratio will play a role
in determining whether glutamine is metabolized oxidatively or reductively. Regarding the
carbon entry into the TCA cycle via AcCoA, there are at least two upstream mechanisms
explaining how carbon entry (and subsequent downstream metabolic changes) are regulated.
In the case of hypoxia, decreased carbon entry into the TCA cycle is driven at least in part
by PDK1-mediated inhibition of pyruvate dehydrogenase, while complex I/III inhibition
decreases carbon entry into the TCA cycle through a decrease in the NAD+/NADH ratio.
The latter is the result of mitochondrial electron transport inhibition, which in turn decreases
pyruvate to AcCoA conversion likely via cofactor coupling. By extension, any condition
that affects the α-ketoglutarate/citrate ratio, regardless of the upstream regulation that
initiates this change, is predicted to alter reductive versus oxidative glutamine utilization and
consequently the fueling source for proliferation relevant fatty acid synthesis. Although our
approach has the limitation that we cannot conclude whether reductive carboxylation takes
place in the mitochondria or the cytosol, this mechanistic understanding allows for the first
time predictions of environmental and genetic conditions, which promote reductive
glutamine utilization and might lead to the development of drugs inhibiting this process.
Although reductive carboxylation has mainly been investigated in cancer cells there is
evidence that at least some non-transformed cell also use this pathway (e.g. non-transformed
cells from brown fat (differentiated brown adipocytes22), lung (MRC55), prostate (p69,
unpublished data by S-M Fendt), and normal lymphocytes5 Hence, this mode of regulation
may allow carbon metabolism to rapidly adapt to changing growth conditions. In this way,
the cell can immediately switch carbon source utilization without involving complex
transcriptional or allosteric regulation and ensure optimal substrate usage to support growth
under various conditions. Furthermore, this mechanism is a consequence of any upstream
event altering α-ketoglutarate and/or citrate levels and requires no further energy
investment. Yet, to which extent NAD(P)+/NAD(P)H levels, which are cofactors coupled to
the α-ketoglutarate to citrate ratio and affect the activity of enzymes such as glutamate
dehydrogenase, influence the reaction direction remains to be determined, but some
influence is likely based on kinetic considerations. As a result, targeting reductive glutamine
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metabolism for therapeutic benefit may require an approach that impacts intrinsic properties
of the metabolic network, rather than interruption of signaling events that indirectly
influence the process.
Methods
Cell lines and cell culture conditions
All cell lines were obtained from ATCC. All experiments were performed in DMEM
(Mediatech) with 10% dialyzed fetal bovine serum (Invitrogen) and 1% pen/strep
(Mediatech) and glucose or glutamine with either U-13C glucose (CLM-1396 Cambridge
Isotopes), U-13C glutamine (605166 Sigma) or 5-13C glutamine (CLM-1166 Cambridge
Isotopes). Cell lines were treated for 1day or in case of fatty acid labeling for 3 days. Growth
conditions were altered in the following ways: AICAR 0.25 mmol/L (143B), antimycin 2
μg/ml (PC3) and 20ng/ml (A549, 143B), citrate 0.3 and 1.2 mmol/L (A549), DCA 5mmol/L
(A549, PC3), FCCP 10 μmol/L (PC3) and 2.5 μmol/L (143B), hypoxia 1 % (A549, 143B,
PC3), lactate 25 mmol/L (A549, 143B), metformin 1 mmol/L (A549, 143B), myxothiazol 1
μmol/L (PC3), NMN 25mmol/L (A549, 143B), oligomycin 5 μmol/L (PC3) and 2.5 μmol/L
(143B), rotenone 1 μg/ml (PC3) and 10 ng/ml (A549, 143B), TTFA 400 μmol/L (PC3). All
compounds were obtained from Sigma.
Oxygen consumption
Oxygen consumption was measured with an Oxytherm instrument (Hansatech). Cells were
trypsinized and resuspended in fresh media. Oxygen consumption of detached cells was
measured for 10min. The slope of the linear range was used to calculate rates. Error bars are
from biological replicates.
Carbon contribution to TCA cycle and palmitate
To asses metabolite levels and metabolite labeling we applied the methods described in
Metallo et al5. In brief labeled tissue cultures were washed with saline and metabolism was
quenched with −20°C cold 65% methanol. After cell scraping in 65% methanol, −20°C cold
chloroform was added and the samples were vortexed at 4°C to extract metabolites. Phase
separation was achieved by centrifugation at 4°C. Methanol phase (polar metabolites) and
chloroform phase (fatty acids) were separated and dried applying constant air flow. Dried
metabolite samples were stored at −80°C.
Polar metabolite samples were derivatized with methoxyamine (TS-45950 Thermo
Scientific) for 90min at 40°C and subsequently with N-(tert-butyldimethylsilyl)-N-methyl-
trifluoroacetamide, with 1% tert-Butyldimethylchlorosilane (375934 Sigma) for 60min at
60°C. Fatty acids were esterified with sulfuric acid/methanol for 120min at 60°C and
subsequently extracted with hexane. Isotopomer distributions of polar metabolites and fatty
acids were measured with a 6890N GC system (Agilent Technologies) combined with a
5975B Inert XL MS system (Agilent Technologies). One microliter of samples was injected
in splitless mode with an inlet temperature of 270 °C onto a DB35MS column. The carrier
gas was helium with a flow rate of 1ml/min. For the measurement of polar metabolites the
oven was held at 100°C for 3 minutes and then ramped to 300°C with a gradient of 2.5°C/
min. For fatty acid samples the oven was held at 80°C for 1 min and ramped with 5°C/min
to 300°C. The MS system was operated under electron impact ionization at 70eV. A mass
range of 100–650amu was scanned.
Isotopomer distributions were extracted from the raw ion chromatograms using a custom
Matlab M-file, which applies consistent integration bounds and baseline correction to each
ion29. Additionally we corrected for naturally occurring isotopes using the method of
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Fernandez et al30. Total contribution of carbon was calculated using the following
equation 31:
Here n is the number of C atoms in the metabolite, i the different mass isotopomers and m
the abundance of a certain mass. In the case of lactate supplement, total pyruvate
contribution instead of total glucose contribution is depicted and M+3 of α-ketoglutarate
from U-13C glutamine was used as a measure for AcCoA contribution to α-ketoglutarate.
For relative metabolite levels the total ion count was normalized to the internal standard
norvaline and to cell number counted with an automated cell counter (Nexcelom).
Isotopomer distributions of fatty acids were further fitted to an isotopic spectral analysis
model previously described5. Isotopic spectral analysis is a nonlinear regression method for
fitting the gas chromatography - mass spectrometry data to a model for biosynthesis with
two unknowns, D, the fractional contribution of the labeled precursor to the biosynthetic
precursor pool, and g(t), the fraction of newly synthesized product present at time t. 21, 22.
During citrate supplementation we specifically focus on the ratio between oxidative and
reductive glutamine conversion because absolute contributions cannot be inferred due to
variations in the label dilution at different amounts of supplementation. Moreover, high
concentrations of unlabeled and residual citrate from the media prevented the accurate
measurement of label in this pool, hence the ratio of oxidative versus reductive glutamine
utilization was determined from the measurement of M+4 in fumarate, malate and aspartate
(oxidative contribution) and M+3 in fumarate, malate and aspartate (reductive contribution)
(Supplementary Figure S2c).
Net reductive glutamine fluxes to palmitate in the presence or absence of antimycine,
oligomycine or TTFA were calculated as described by Metallo et al.5 based on the fractional
contribution of reductively utilized glutamine and the fraction of newly synthesized
glutamine (D and g(t) from the isotopic spectral analysis model) combined with cell
numbers and growth rates5.
Raw data are depicted in Supplementary Data 1. Error bars are from biological replicates.
We verified for our data set that glutaminolysis, protein turnover and CO2 refixation can be
neglected. This is necessary because glutamiolysis can occur in mammalian cells32 and CO2
refixation has been shown to be important in microbes33. Therefore, we analyzed M+0 from
pyruvate on a U-13C glutamine tracer (significantly altered M+0 indicates glutaminolysis),
M+5 of glutamine from a U-13C glutamine tracer (significantly altered M+5 indicates
protein turnover) and M+1 and M+2 from a 1-13C glutamine tracer (M+2 indicates CO2
refixation) (Supplementary Figure S7). In accordance with previous reports5, 34, 35 we found
that, glutaminolysis, protein turnover and CO2 refixation can be neglected.
NAD+/NADH ratio
The protocol used to extract NAD+/NADH from cells was adapted from a previously
described method36. In brief tissue culture cells were washed with ice cold phosphate
buffered saline and immediately quenched with liquid nitrogen. −20 °C cold extraction
solution (40% methanol, 40% acetonitrile, 20% buffer) was added and plates were incubated
at −20 °C for 15 minutes. Cells were scraped on dry ice and centrifuged at 4 °C. The
supernatant was collected and the remaining pellet re-extracted twice with extraction
solution. The supernatant was dried and analyzed by high pressure liquid chromatography.
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The quenching protocol was validated by measuring the ATP, ADP and AMP with liquid
chromatography – mass spectrometry. The calculated energy charge was 0.73.
Dried extracts were dissolved in water and separation of compounds was achieved by HPLC
using an Agilent (C8) 2.6 × 250 mm, 5 μmol/L particle column (Agilent Technologies). The
HPLC method was adapted from a published method37 and verified. Mobile phase flow rate
was 1mL/min. Eluent A (50 mmol/L potassium phosphate dibasic and 8 mmol/L
tetrabutylammonium bisulfate aqueous adjusted to pH 5.8) and eluent B (50 mmol/L
potassium phosphate dibasic and 8 mmol/L tetrabutylammonium bisulfate aqueous solution
adjusted to pH 5.8 with 40 % acetonitrile) were applied with a time dependent gradient.
Absorbance of NAD was detected at 254 nm wavelength and NADH was detected at 254
nm and 340 nm. The method was verified with calibration curves, which are depicted in
Supplementary Figure S8. Error bars are from biological replicates.
Western Blot
PDH and phospo-PDH antibodies were obtained from Invitrogen or Calbiochem, respectivly
and diluted to 1μg/ml or 0.25μg/ml, respectively.
Statistics
Error bars depict standard deviation. R and p values for the depicted correlations were
calculated with the Matlab integrated function corrcoef: [R,P]=corrcoef returns P, a matrix
of p-values for testing the hypothesis of no correlation. Each p-value is the probability of
getting a correlation as large as the observed value by random chance, when the true
correlation is zero. P values were also calculated for bar graphs using a student’s T-test
(two-tailed, unequal variance) to determine whether two samples are likely to have come
from the same two underlying populations that have the same mean.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Reductive carboxylation correlates with concomitant metabolic parameters. (a) Reductive
(α-ketoglutarate to citrate) versus oxidative (citrate to α-ketoglutarate) flux and concomitant
network reactions and metabolites. Reductive glutamine contribution to citrate (b),
alterations in citrate and α-ketoglutarate levels (c), and AcCoA contribution to α-
ketoglutarate (M+2 of α-ketoglutarate from U13C glucose) as well as total glucose
contribution to citrate (d), for different stress conditions. Correlation between reductive
glutamine contribution to citrate and the α-ketoglutarate to citrate ratio (e), and AcCoA
contribution to α-ketoglutarate as well as total glucose contribution to citrate (f) Ctrl denotes
standard culture condition. All error bars indicate the standard deviation. All p-values
(students T-test, two tailed, unequal variance) and error bars are calculated from two
independent replicates.
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Figure 2.
Metabolic parameters modulate reductive carboxylation. (a) Lactate supplementation
(25mmol/L) in the media prohibits glucose conversion to lactate and thus forces an
increased glucose contribution to the TCA cycle. Flux and metabolite state in standard
growth condition (left), hypoxia or complex I/III inhibition (middle), and hypoxia or
complex I/III inhibition with lactate (right). Thickness of the arrows and the size of the
metabolites indicates the magnitude of alteration. AcCoA contribution to α-ketoglutarate
(calculated from a U-13C glutamine tracer: M+3 from glutamine is highly correlated with M
+2 from glucose in A549: R= 0.998, p=0.0001) (b), α-ketoglutarate/citrate ratio (c), and
reductive glutamine contribution to citrate (d), for different stress conditions with and
without lactate supplementation. All error bars indicate the standard deviation. All p-values
(students T-test, two tailed, unequal variance) and error bars are calculated from two
independent replicates.
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Figure 3.
The α-ketoglutarate/citrate ratio determines reductive glutamine utilization. (a) Acetate is a
third carbon source beside glucose and glutamine that fuels the citrate pool. (b) α-
ketoglutarate/citrate ratio, and (c) reductive glutamine contribution to citrate normalized to
the total glutamine contribution to citrate, with and without acetate supplementation in the
control condition and in the presence of metformin. (d) Ratio of oxidative versus reductive
glutamine utilization in the presence of metformin with and without acetate measured with a
U13C-glutamine tracer. (e) Glutamine contribution to palmitate in metformin treatment
conditions with and without acetate supplementation. (f) Ratio of oxidative versus reductive
glutamine utilization in the presence of metformin with and without different concentrations
of citrate measured with a U13C-glutamine tracer determined from fumarate, malate and
asparate. All error bars indicate the standard deviation. p-values are < 0.05. All p-values
(students T-test, two tailed, unequal variance) and error bars are calculated from two
independent replicates.
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Figure 4.
Reductively derived citrate correlates with metabolic parameters in 143B cells. (a)
Reductive glutamine contribution to citrate. (b) AcCoA contribution to α-ketoglutarate. (c)
Total pyruvate contribution to citrate. (d) Alterations in citrate and α-ketoglutarate levels.
Correlation between the reductive glutamine contribution to citrate and (e) the AcCoA
contribution to α-ketoglutarate, (f) the total pyruvate contribution to citrate, (g) the relative
citrate and α-ketoglutarate levels and (h) the α-ketoglutarate/citrate ratio. In case of lactate
supplementation M+3 in α-ketoglutarate from U-13C glutamine instead of M+2 in α-
ketoglutarate from U-13C glucose was used. Ctrl denotes standard culture condition. All
error bars indicate the standard deviation. The correlation criteria were R > 0.7 or R < −0.7,
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and p < 0.05. All p-values (students T-test, two tailed, unequal variance) and error bars are
calculated from two independent replicates.
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Figure 5.
Reductively derived fatty acids correlates with metabolic parameters in PC3 cells.
Correlation between the reductive glutamine contribution to fatty acids (palmitate) and (a)
the AcCoA contribution to α-ketoglutarate, (b) the total glucose contribution to citrate, and
(c) the α-ketoglutarate/citrate ratio. Ctrl denotes standard culture condition. All p-values are
calculated with students T-test (two tailed, unequal variance).
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Figure 6.
PDK1 regulates carbon entry into the TCA cycle in hypoxia. (a) Reductive glutamine
contribution to citrate for different stress conditions with and without the pyruvate
dehydrogenase kinase (PDK) inhibitor DCA. (b) NAD+/NADH ratio for different stress
conditions. Ctrl denotes standard culture condition. All error bars indicate the standard
deviation. All p-values (students T-test, two tailed, unequal variance) and error bars are
calculated from three independent replicates.
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Figure 7.
NAD+/NADH ratio limits carbon entry into the TCA cycle. (a) NMN supplementation
(25mmol/L) increased NAD+ level and thus increased NAD+/NADH ratio, which leads to
increased glucose flux through pyruvate dehydrogenase. Flux and metabolite state in
standard growth condition (left), hypoxia or complex I/III inhibition (middle), and hypoxia
or complex I/III inhibition with NMN (right). Thickness of the arrows and the size of the
metabolites indicate the magnitude of alteration. NAD+/NADH ratio (b), AcCoA
contribution to α-ketoglutarate (c), reductive glutamine contribution to citrate (d), in the
presence of metformin with and without NMN supplementation. AcCoA contribution to α-
ketoglutarate (e), and reductive glutamine contribution to citrate (f), in the presence of
metformin and pyruvate dehydrogenase kinase inhibitor DCA with and without NMN
supplementation. All error bars indicate the standard deviation. P-values between with and
without NMN supplementation are < 0.05. All p-values (students T-test, two tailed, unequal
variance) and error bars are calculated from two independent replicates.
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Figure 8.
Reductive glutamine carboxylation is a function of the α-ketoglutarate to citrate ratio. In
standard growth conditions proliferation relevant fatty acids are produced mainly from
glucose (left). Any stress condition leading to an increased α-ketoglutarate to citrate ratio
alters glutamine conversion from oxidative to reductive (right). Subsequently, proliferation
relevant fatty acids are produced mainly from glutamine (right). Dashed lines indicate the
regulatory flow. Size of the metabolites and arrow thickness indicate the magnitude of
alteration.
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